A phase 2 trial of TCMCB07 in colorectal cancer, run by Endevica Bio, now recruiting.
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy is a phase 2 interventional study registered as NCT06937177 by Endevica Bio, with 120 participants planned, started 2025-04-28 and due to reach its primary completion in 2027-10. Interventions recorded: TCMCB07 and Placebo.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.